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Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the 
central nervous system (CNS). MS is one of the most common neurological 
disorders causing disability in young adults. The estimated prevalence of MS in the 
world is 30 per 100,000. The highest prevalence is in Europe (80 per 100,000), 
followed by the Eastern Mediterranean (14.9), the Americas (8.3), the Western 
Pacific (5), South-East Asia (2.8) and Africa (0.3). MS is more common among 
women than men (WHO, 2008). 
Typically, symptoms appear when patients are around 30 years of age. The most 
common symptoms are paresthesia; numbness or weakness in one or more limbs; 
bladder, bowel and sexual dysfunction; dysarthria, ataxia and tremor; optic 
neuritis, trigemal neuralgia, heat intolerance, fatigue, dizziness, lack of sleep, pain, 
cognitive difficulties and depression (Miljkovic & Spasojevic, 2013). Clinically, MS 
is classified based on the clinical course of the disease (Figure 1). About 85% of 
the patients present a relapsing-remitting type (RRMS), which is characterized by 
recurrent episodes of neurological disabilities, caused by inflammation and 
demyelination. These relapses are followed by periods of partial or complete 
recovery. In about half of the RRMS patients, the remission is not complete and 
the disease gradually takes a secondary progressive course (SPMS), in which 
neurological disabilities accumulate without proper recovery. In 15% of the 
patients, the disease course is progressive from disease onset, without remission 
or relapse phases. This type of MS is defined as primary progressive MS (PPMS). 
Progressive relapsing MS (PRMS) is a rare type of MS that initially presents as 
PPMS, but develops neurological exacerbations during the disease progression. 
There is still a fifth type of MS that - contrary to the other disease courses - show 




decades after disease onset (Miljkovic & Spasojevic, 2013; Pittock & Lucchinetti, 




Figure 1: Clinical course of the 4 main types of MS: relapsing-remitting (RRMS), secondary 
progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS). 
 
The pathological hallmark in MS is the formation of demyelinated lesions, also 
called sclerotic plaques, in the white and grey matter of the central nervous 
system. These lesions are the result of a complicated process involving 
inflammation, demyelination and remyelination, oligodendrocyte depletion, 
astrocytosis, and neuronal and axonal degeneration. The lesions can occur 
anywhere of the CNS, but sites as the optic nerve, brainstem, cerebellum and 
spinal cord are more related to clinical deficits (Lassman, 2013; Compston & Coles, 
2008; MacDonald & Ron, 1999).  
MS has long been considered a mere autoimmune disease caused by the invasion 
of myelin-autoreactive lymphocytes across the blood-brain barrier (BBB) and 
choroid plexus. These lymphocytes attack myelin and oligodendrocytes and 
induce an inflammatory cascade that involves macrophage recruitment and 





(Compston & Coles, 2008; Chen et al, 2012). However, new insights have led to a 
different view on the disease. Nowadays, MS is more considered as a chronic, 
gradually aggravating neurodegenerative disease with oligodendrocytes and 
axons as primary affected targets. In this view, primary progressive MS is thought 
to be the “purest” form of MS. In the relapsing-remitting type of MS, an aberrant, 
excessive immune response to antigenic debris (myelin, neurofilaments), caused 
by the ongoing neurodegeneration process, is convoluted on top of the underlying 
neurodegeneration. The continuous neurodegenerative nature of MS becomes 
apparent again in the secondary progressive stage, when aging tones down the 
undulating vigorous immune reactions. The observations that myelin sheath 
degradation in MS starts from within (not by cells attacking from the outside) and 
that all current anti-immune and anti-infiltration drugs for MS can only reduce or 
delay relapses, but cannot stop ongoing degeneration, seem to be in line with 
these new ideas about MS (Stys et al, 2012). 
 
Animal models for multiple sclerosis  
 
Multiple sclerosis is a disease that spontaneously occurs only in humans. From a 
practical and ethical point of view, it is often not possible to perform invasive 
studies in patients. The possibilities for noninvasive investigation of the actual 
pathological processes in the CNS are confined to analysis of postmortem brain 
tissue or imaging techniques that allow detection of lesions, but are not very 
specific for the actual disease processes involved. Therefore, most research still 
relies on the use of animal models that mimic MS. Due to the complexity of MS, 
none of the current animal models for MS is able to mimic all disease aspects, but 




features of the disease. The most commonly used animal models for multiple 
sclerosis are classified in 3 categories: (1) Experimental Autoimmune (or Allergic) 
Encephalomyelitis (EAE); (2) Viral induced demyelination models and (3) Toxin 
induced demyelination models. 
 
Experimental autoimmune encephalomyelitis (EAE) 
 
EAE is the most frequently used animal model for studying the inflammatory 
aspects of MS. EAE has been induced in a wide variety of species, such as mice, 
rats, guinea pigs, rabbits, goats, dogs, sheep and primates (Baxter, 2007).   
EAE is induced by immunizing the animals with CNS antigens emulsified in an 
adjuvant. In general, these antigens are purified myelin, recombinant proteins or 
encephalitogenic peptides of myelin proteins. They cause the activation of 
peripheral antigen-specific T-cells that enter the CNS and induce lesion formation 
(Denic et al, 2011; van der Star et al, 2012). 
The clinical course of the disease depends on the immunization protocol, the 
antigen used and the animal strain. In most cases, symptoms start with weight 
loss and loss of activity, and proceed into motor disability (limb paralysis). In some 
cases, EAE progresses very aggressively and can lead to the death of the animal. 
Although, EAE is a valuable model for research in MS, it is recognized to cause 
severe animal discomfort and, because of that, its use is only justified when other, 
less harmful animal models are not suitable for answering a specific research 







Viral induced model 
 
The hypothesis that a viral infection early in life can trigger the aberrant immune 
response to myelin in the CNS and therefore could be a potential cause of MS has 
led to the use of virus-induced demyelination animal models. So far, a specific 
type of virus has not been unambiguously identified as the potential cause for MS 
(Denic et al, 2010).  
In the most frequently used viral animal model for multiple sclerosis, 
demyelination is induced by the Theiler´s murine encephalomyelitis virus, which is 
a natural pathogen of mice. Infection of mice by the intracerebral injection of the 
virus causes paralysis and encephalomyelitis. The resulting disease can be 
characterized by, in general, 2 phases: (1) the acute phase, which is mild and 
usually subclinical and predominately confined to neurons and (2) the chronic 
phase, exhibiting slow progressive disability, as a consequence of demyelination, 
impaired remyelination, inflammation and axonal damage (Denic et al, 2011; 
Pachner, 2011). 
The disadvantages of this model in comparison to the EAE model is that it can be 
induced only in mice and that the disease manifestations occur months after the 
initial infection (Pachner, 2011). 
 
Toxin induced model 
 
The toxin-induced models are predominately used for studying the demyelination 




Demyelination is induced by focal application or by systemic administration of the 




Cuprizone [oxalic acid bis(cyclohexylidene hydrazide)] is a copper chelating agent 
and the most frequently used toxin to induce demyelination in the CNS by 
systemic administration. The most common demyelination protocol comprises the 
feeding of C57Bl/6 mice with 0.2% cuprizone for 5-6 weeks. The model is species, 
strain and age dependent. Cuprizone has failed to induce demyelination in several 
adult rat strains (Carlton, 1969; Love, 1988). Only a single report has been 
published, in which cuprizone-induced demyelination in young Wistar rats was 
observed (Adamo et al, 2006). The administration of cuprizone in mice induces 
oligodendrocyte death without significant damage to other neural cell types. This 
activity of cuprizone requires microglia activation and their secretion of pro-
inflammatory cytokines (Pasquini et al, 2007). Short exposure to the cuprizone 
diet induces acute demyelination, which is most prominent in the corpus callosum 
and the cerebellar peduncle. Demyelination is followed by spontaneous 
remyelination when normal chow diet is restored. Chronic demyelination occurs 
when animals are kept on a cuprizone diet for a long period of time (12 weeks or 
more) (Kipp et al, 2009; Torkildsen et al, 2008; Matsushima & Morell, 2001). 
The highly reproducible, the simplicity of the protocol, the fast demyelination 
induction, the spontaneous remyelination after restoration of normal food, as 
well as the lack of peripheral cell infiltration, make the cuprizone-induced model a 








The most commonly used toxins to induce focal demyelinated lesions are 
ethidium bromide and lysolecithin. Because these toxins are injected directly into 
the CNS, demyelination can be induced in all species and in different CNS regions 
of preference. 
Lysolecithin (lysophosphatidylcholine, LPC) is an activator of phospholipase A2 
that disrupts membranes, especially damaging myelin. This induces an acute 
inflammatory response, including microglia activation and monocyte infiltration at 
the site of the lesion. Lysolecithin has a short half-life (5 hours) and remyelination 
occurs spontaneously, already evident 14 days after injection and almost 
completed by 6 weeks (Denic et al, 2011; van der Star, 2012). 
Ethidium bromide is a DNA intercalating agent that has a cytotoxic effect on all 
nucleated cells. Therefore, the damage induced by ethidium bromide is not 
specific for myelin producing cells alone (van der Star, 2012). Demyelination 
reaches a peak at 2 weeks and the remyelination predominates at 4 weeks after 




Animal models are indispensable for studying ongoing in vivo processes and to 
better understand disease mechanisms. Eventually, the results of animal studies 
need to be translated to and validated in patients. Imaging techniques are 
valuable tools for monitoring the in vivo processes and can be applied both in 




research. In MS research, the development of new imaging techniques and/or the 
validation of new imaging applications are still needed, as the existing methods do 
not suffice.  
“The capacity to image cellular and molecular targets in vivo” defines the term 
molecular imaging. Positron emission tomography (PET) is probably the best 
example of a molecular imaging device.  PET allows the quantification of tracer 
distribution and redistribution, providing biochemical and physiological 
information of the living organism. The advance in PET instrumentation has made 
the technology also available for preclinical research, which allows the translation 
of preclinical results to human applications (Grenier & Brader, 2011; Hutchins et 
al, 2008).  
 
Positron emission tomography 
 
Positron emission tomography (PET) is a molecular imaging technique that 
quantitatively and non-invasively measures biochemical and physiological 
processes in vivo by using specific targeting molecules labeled with positron 
emitting isotopes. These labeled molecules are called PET tracers or PET 
radiopharmaceuticals (Paans et al, 2002; van den Hoff, 2005). 
The positron emitters, such as 15O, 11C, 13N, 18F, are neutron deficient isotopes that 
decay by the emission of a positively charged electron: a positron. This positron 
travels through the surrounding tissue losing energy due to collision with 
electrons. When the energy of the positron is sufficiently low, it can combine with 
an electron and annihilation can occur. In this process, the mass of the positron 
and electron is converted into two gamma rays with an energy of 511 keV, 





of momentum, these gamma rays travel in opposite directions (at an angle of 180° 
from each other) (Townsend, 2004; Basu et al, 2011). 
The emitted gamma rays are detected by a circular (360°) detector structure, 
using the principle of coincidence detection. Coincidence detection means that 
the detection is only accepted as a true event if the two gamma rays are almost 
simultaneously (typically within 100 ns) detected by opposite detectors. Each 
coincidence event represents a straight line in space between the two detectors, 
on which the point of origin of the emission of the positron is located. This line is 
called a line-of-response (LOR). A combination of LORs is used for reconstruction 
of a computerized image, representing the 3D distribution of the injected 
radiopharmaceutical in the tissue (Andreyev & Celler, 2011; Townsend, 2004). 
Besides physical properties of PET tracers, the chemical and biological 
characteristics of these molecules determine whether the radiopharmaceutical 
can be successfully used for brain imaging. These characteristics include binding 
affinity and specificity, metabolism and elimination rates, and brain penetration 
(Wadsak & Mitterhauser, 2010). Only complete knowledge about the injected 
radiopharmaceutical, gathered by preclinical and clinical research, can guarantee 
the correct interpretation of the resulting image. 
 
Aim and outline of the thesis 
 
The progressive characteristic and the lack of an effective therapy, make constant 
monitoring a crucial factor in the evaluation of disease progression and treatment 
effects in multiple sclerosis. Non-invasive imaging techniques are the best option 
for monitoring the disease progression and evaluating new drugs, since they can 




imaging techniques for disease-specific processes in MS still need to be evaluated 
and validated in models of the disease, before they can be implemented in clinical 
practice. 
Imaging techniques can also be extremely important in preclinical research, 
enabling longitudinal studies of ongoing processes that could help to understand 
mechanisms involved in disease progression. PET imaging could become a tool to 
specifically monitor different disease-related aspects of MS in a non-invasive 
manner. Therefore, the aim of the work described in this thesis was to evaluate 
and compare different PET tracers with potential for imaging multiple sclerosis 
hallmarks. For this purpose, different approaches were used: i. The cuprizone-
induced mouse model was used to evaluate [11C]CIC and [11C]MeDAS as candidate 
PET tracers for imaging demyelination and remyelination processes. ii. The 
lysolecithin rat model was applied to assess the feasibility of monitoring glucose 
metabolism, neuroinflammation, demyelination and remyelination in focal lesions 
over time. iii. The lysolecithin rat model was also used for evaluating the 
pharmacokinetic proprieties of [11C]CIC, [11C]MeDAS and [11C]PIB and for testing 
the ability of these tracers to image focal demyelination and remyelination. iv. 
Finally, the feasibility of PET imaging to evaluate treatment efficacy was 
investigated by monitoring longitudinal changes in neuroinflammation and 
demyelination in EAE rats treated with dexamethasone or placebo. A brief outline 
of this thesis is given below. 
 Chapter 2 reviews the available PET tracers for application in MS and 






 Chapter 3 describes the comparison of two PET tracers for imaging 
demyelination and remyelination processes in the cuprizone-induced mouse 
model for multiple sclerosis. 
 Chapter 4 shows the potential of PET imaging for monitoring transient 
changes in different characteristics of focal demyelinated lesions in the 
lysolecithin rat model: glucose metabolism, neuroinflammation, demyelination 
and remyelination. 
 Chapter 5 describes the results of the kinetic modeling studies of 3 PET 
tracers for myelin imaging and presents a comparison of the ability of these 
tracers to detect demyelination and remyelination processes in a focal lesion in 
the lysolecithin rat model.   
 Chapter 6 describes the monitoring of disease progression and the 
therapeutic effects of dexamethasone in the EAE rat model by PET imaging of 
neuroinflammation, demyelination and T cell infiltration.  
 Chapter 7 gives some future perspectives for in vivo monitoring of disease 
progression in MS with PET. 
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